INDIA —Indian pharmaceutical manufacturer Mankind Pharma, operating through its subsidiary Mankind Pharma (Netherlands) B.V., has signed a definitive agreement to acquire a 70% equity stake in Armed Cell Therapeutics B.V. for 48 million euros (52.2 million US dollars). The cross-border transaction provides Mankind with controlling interest in the Belgium-incorporated biotechnology enterprise, establishing a direct foothold in advanced oncology biotherapeutics.
Mankind Pharma is a major Indian pharmaceutical corporation listed on the BSE and NSE that produces branded generics, consumer healthcare products, and active pharmaceutical ingredients. Armed Cell Therapeutics B.V. is a European clinical-stage biotechnology company that specializes in developing engineered chimeric antigen receptor T-cell therapies for hematological malignancies and solid tumor cancers.
Armed Cell Therapeutics focuses on developing multi-antigen and armored CAR-T assets designed to prevent therapeutic resistance and overcome tumor microenvironments, alongside research into in vivo cell therapy generation. The company's pipeline includes lead research programs targeting non-Hodgkin lymphoma and small cell lung cancer, supported by research and development operations across the United States and Europe.
This transaction underscores a growing strategic pivot among leading Indian drugmakers from traditional generic formulations toward high-margin, innovation-driven biopharmaceuticals. For healthcare investors, global biotechnology firms, and oncology care providers, Mankind's capital injection accelerates early-stage cell therapy development while creating a long-term commercial platform to expand access to complex biological treatments across emerging and developed healthcare markets.
